ncRNA biotech company Cardior Pharmaceuticals announced on Wednesday that it has elected Russell Greig, BSc and PhD as its board of directors' independent chairman.

As the company's board chair, Dr Greig is committed to creating value for both shareholders and patients, prepared to enter mid-stage clinical development, advance its broad pipeline of ncRNA therapeutics for cardiac diseases, replacing its general partner and managing director, Dr Markus Hosang, who will step down from his current board chair position but will remain as its vice chairman.

Most recently, Dr Greig has served as president of SR One, GlaxoSmithKline's corporate venture group.

Previously, Dr Greig has worked as president of GlaxoSmithKline's Pharmaceuticals International from 2003 to 2008, senior vice president of worldwide development from 2000-2003 as well as a member of the GlaxoSmithKline's corporate executive team.